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Abstract
Background: Despite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech
regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU
marketing licence in the last 7 years. Here, we outline some of the historical reasons for this paucity of licensed
innovative regenerative medicines. We discuss the challenges to be overcome to expedite the development of this
complex and rapidly changing area of medicine, together with possible reasons to be more optimistic for the future.
Discussion: Several factors have contributed to the scarcity of cutting-edge regenerative medicines in clinical practice.
These include the great expense and difficulties involved in planning how individual therapies will be developed,
manufactured to commercial levels and ultimately successfully delivered to patients. Specific challenges also exist when
evaluating the safety, efficacy and cost-effectiveness of these therapies. Furthermore, many treatments are used without
a licence from the European Medicines Agency, under “Hospital Exemption” from the EC legislation. For products which
are licensed, alternative financing approaches by healthcare providers may be needed, since many therapies will have
significant up-front costs but uncertain benefits and harms in the long-term. However, increasing political interest and
more flexible mechanisms for licensing and financing of therapies are now evident; these could be key to the future
growth and development of regenerative medicine in clinical practice.
Conclusions: Recent developments in regulatory processes, coupled with increasing political interest, may offer some
hope for improvements to the long and often difficult routes from laboratory to marketplace for leading-edge cell or
tissue therapies. Collaboration between publicly-funded researchers and the pharmaceutical industry could be key to the
future development of regenerative medicine in clinical practice; such collaborations might also offer a possible antidote
to the innovation crisis in the pharmaceutical industry.
Keywords: Regenerative medicine, European Medicines Agency, Cell therapy, Gene therapy
Background
“Cure for blindness found” proclaimed a front page head-
line of a UK newspaper [1]. The article’s text revealed a
different story, of a promising line of research based on
clinical trial data from just a single patient treated with an
embryonic stem cell therapy, for which it “will be some
months before the full impact of it [the treatment] on her
sight is known”. Although the fullness of time may yet re-
veal this new treatment to be a cure for blindness, this ex-
ample illustrates the weight of expectation often placed on
innovative new ‘regenerative medicines’ to transform the
future of healthcare. Regenerative medicine – which is not
a new field of medicine as it encompasses bone marrow
or organ transplants – deals with the process of replacing
or regenerating human cells, tissues or organs to restore
or establish normal function [2]. Most new regenerative
medicines are classed by the European Medicines Agency
(EMA) as being ‘advanced-therapy medicinal products’
(ATMPs), which are engineered regenerative medicines
encompassing cell-based therapies (often using stem cells
or progenitor cells to produce tissues), gene therapies and
tissue-engineered therapies.
The Committee for Advanced Therapies is the EMA
committee responsible for assessing the quality, safety and
efficacy of ATMPs (and for following scientific develop-
ments in the field). Several EMA regulatory pathways exist
to facilitate accelerated access to treatments where there is
an unmet patient need. These include approval under
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exceptional circumstances (1993), conditional marketing
authorisation (2005), accelerated assessment (2005), parallel
scientific advice between EMA and Food and Drug Admin-
istration (FDA; 2009), and the adaptive licensing pilot
programme (2014). Nevertheless, despite 318 relevant trials
having been performed in Europe between 2004 and 2010,
[3] only eight ATMPs have been granted a marketing li-
cence by the EMA, namely ChondroCelect (2009), Glybera
(2012), MACI (2013), Provenge (2013), Holoclar (2015),
Imlygic (2015), Strimvelis (2016), and Zalmoxis (2016). The
main sponsors were academic organisations, charities and
small companies, all of which are stakeholders who tend to
have limited resources with regard to both financing and
the capacity to navigate the required regulatory procedures
[3]. This mismatch between the number of promising ideas
and translation to actual patient benefit [4] may partly be
due to key differences between regenerative medicines and
conventional pharmaceuticals. Regenerative medicines are
often truly personalised and therefore expensive and diffi-
cult to manufacture; evaluation of their efficacy, safety and
cost-effectiveness may also be challenging [5, 6].
Nevertheless, there appears a new sense of urgency to ad-
dress these issues. In the UK, a House of Lords Science and
Technology Committee inquiry into regenerative medicine
identified barriers to translation and commercialisation and
recommended solutions. In response to its findings – pub-
lished in 2013 [7] – the National Institute for Health and
Care Excellence (NICE) was asked to commission a study
to assess whether its current appraisal methods and pro-
cesses were appropriate to evaluate regenerative medicines.
We were part of the team that performed that study, which
included an assessment of previous evaluations of regenera-
tive medicines by NICE, the EMA and the FDA [8, 9].
More recently (in April 2016), the House of Commons Sci-
ence and Technology Committee announced it was under-
taking an inquiry into regenerative medicine, which will
report in early February 2017. In this article, we discuss
some of the historical causes for the scarcity of licensed in-
novative regenerative medicines, together with possible rea-
sons to be more optimistic for the future. This paper arose
as a result of our work on the aforementioned study for




Although the randomised controlled trial is the expected
level of evidence for regulatory assessments, it is likely that
many evidence submissions for regenerative medicines will
comprise small, single-arm, short-term, early phase clinical
trials. These sub-optimal study designs are likely to produce
biased and imprecise results. However, the use of such de-
signs is not inevitable and is unlikely to be through choice,
but is instead a consequence of the type of patients targeted
by new therapies. Populations with rare, severe or advanced
disease may be very small, and therefore adequate recruit-
ment to trials with two treatment arms would require many
centres, much time and great expense. Further, where no
alternative treatments exist, and patients have life-
threatening or severe disease, randomisation to a control
group is likely to be ethically unacceptable or problematic,
as may the requirement for lengthy follow-up before licence
submission. This is particularly likely to be a problem when
initial studies on small numbers of patients have shown
spectacular results [10]. Trials utilising alternative ap-
proaches to conventional randomisation might also be con-
sidered when rare diseases are studied [11]. For example,
responsive-adaptive randomisation maximises allocation to
the most effective treatment and minimises the required
sample size. Such a ‘play the winner’ design has the poten-
tial to reduce the number of patients allocated to less effect-
ive treatment, therefore reducing the ethical concerns
associated with randomisation, though it is limited to stud-
ies that assess rapidly available outcomes. However, for new
types of study design such as this, the magnitude of the
risks of bias are not yet well understood [12]; in reality,
single-arm studies are therefore most likely to be submitted
for licensing purposes.
Another issue often encountered is the use of surrogate
endpoints – laboratory or physiological measures used to
predict or provide an early measure of therapeutic effect –
rather than real clinical (patient-important) endpoints. Sur-
rogate endpoint data are quicker and easier to acquire than
real clinical endpoint data, thus saving valuable time in the
licensing process (for both manufacturers and patients).
However, there is often considerable uncertainty about the
strength of the relationship between a given surrogate and
its relevant real clinical endpoint; this is problematic be-
cause trial results based on surrogate endpoints are not
likely to be reliable if the surrogate has not been properly
validated. It is therefore recommended that, before a surro-
gate outcome is accepted, a systematic review should be
conducted examining the evidence for the validation of the
surrogate-final outcome relationship. To validate a surro-
gate endpoint such reviews must demonstrate that there is
adequate evidence from several sources, including clinical
trials, epidemiological/observational studies and patho-
physiological studies (of biological plausibility of the
relationship) [13].
Additionally, for treatments studied in highly specialised
settings, scepticism about results may arise from evidence
suggesting that single-centre trials tend to produce signifi-
cantly larger effect estimates than multi-centre trials. A
systematic review of 82 critical care medicine randomised
controlled trials found significantly larger treatment ef-
fects for all-cause mortality in single-centre trials when
compared with multi-centre trials (ratio of odds ratios,
0.64; 95% CI, 0.47–0.87) [14]. Where ATMPs are likely to
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be delivered from more than just a single clinic site, effi-
cacy results from single-centre trials should be considered
cautiously by decision makers.
The implications of such evidential problems will largely
depend on both the level of unmet need in the studied
population and the likeliness of cure or improvement with-
out experimental treatment. This can be illustrated by com-
paring two quite recently licensed therapies that claimed to
meet unmet patient needs: Holoclar (a stem cell-based
therapy for treating corneal lesions resulting from burns to
the eye) and Glybera (a gene therapy for treating familial
lipoprotein lipase deficiency with associated pancreatitis). It
seems Holoclar and Glybera had very different approval
histories, primarily due to differences in the likelihood of
patient improvement without new therapy. Despite the
clinical evidence for Holoclar being based on uncontrolled
retrospective data, the results (approximately half the pa-
tients had improved visual acuity) were still sufficiently im-
pressive for the EMA to grant a conditional licence on the
first application. The prospective confirmatory study re-
quired as part of the EMA’s conditional approval should
clarify Holoclar’s efficacy and safety.
The application for Glybera was also supported by
single-arm trial evidence. However, while the evidence
for Holoclar was deemed sufficiently robust, for Glybera,
there were concerns that the apparent treatment benefit
may have been due to chance, resulting in Glybera’s long
and protracted route to marketing authorisation. Nega-
tive committee opinions were issued in June 2011, with
approval finally granted in July 2012 with a more re-
strictive licence than was originally applied for. In 2015,
the manufacturer of Glybera dropped plans to seek ap-
proval for the therapy in the US following the FDA’s
request for further clinical data.
As outlined earlier, the EMA has several regulatory path-
ways that attempt to create a balance between shorter ap-
proval times for promising medicines for populations with
high unmet medical needs, and ensuring a flow of evolving
satisfactory information on efficacy and safety. The most re-
cent update – the adaptive pathways pilot programme –
utilises existing regulatory processes, and is a prospectively
planned adaptive approach to bringing treatments to mar-
ket with an initial focus on patients with a high unmet
need. It will be more of a staggered, iterative system than
previous approval pathways. Such a ‘life-cycle approach’ to
acquiring and (re)assessing evidence will consider the basis
of decision-making in the stages of a product’s life cycle,
namely development, licensing, reimbursement, monitor-
ing/post-licence evidence and utilisation [15, 16].
Improvements to this life-span approach are developing
at pace. For example, with Medicine Adaptive Pathways to
Patients the development plan across target populations
and indications will be agreed up-front with the EMA.
Plans may include a range of studies, such as randomised
controlled trials, single-arm studies, pragmatic trials and
other forms of real world study [17]. A newly formed pub-
lic–private project called ADAPT SMART (Accelerated De-
velopment of Appropriate Patient Therapies: a Sustainable,
Multi-stakeholder Approach from Research to Treatment-
outcomes), funded by the EU Innovative Medicines Initia-
tive, focuses on laying the foundations for Medicine Adap-
tive Pathways to Patients to be put into practice in Europe.
The challenge for ADAPT SMART is to develop an ap-
proach to adaptive pathways that aligns the needs of all
stakeholders, including patients, member state payers, regu-
lators, medical practitioners and the industry [18]. Finally,
the recent proposals announced by the UK Department of
Health (2016) [19] to develop a more enabling environment
for ‘strategically important transformative products’ are
regarded as an additional vehicle through which ATMPs
might be fostered. Crucial to this will be the establishing of
‘accelerated access partnerships’ between public and private
sectors and the NHS of a form not seen before, suggesting
that its success will depend as much on identifying trans-
formative processes as it will on products [19].
Development of ideas and scale-up to commercialisation
Most new regenerative medicines are developed by aca-
demic research institutions or small- and medium-sized
enterprises. Ideas for new therapies are not uncommon,
but it is difficult for new centres to enter the field under
existing regulations; producing regenerative medicines in
accordance with good manufacturing practices (to en-
sure quality, safety and efficacy) is expensive, and the
ongoing costs are frequently overlooked by academic
centres with no history of cell therapy manufacture.
Successful academic centres are often those with pre-
existing quality management systems and staff experi-
enced in manufacturing more conventional cell therapy
products (e.g. those relating to haematopoietic stem cell
transplantation and lymphocyte infusion) [20].
The wide variation evident across the types of new cell-
based medicines [21] highlights the importance of careful
consideration of how individual therapies will be devel-
oped, manufactured and ultimately successfully delivered
to patients in clinical practice settings to commercially vi-
able levels. Key differences in issues will also arise depend-
ing on which of the two main types of cell is being used
when developing a new therapy: autologous (bespoke) cell
therapies, which are derived from an individual patient’s
own cells and allogeneic (universal) cell therapies which
are derived from a donor. A clear understanding of what
will be needed for scale-up to commercial levels is particu-
larly important. Autologous therapies have advantages
over allogeneic therapies in terms of smaller start-up
costs, simpler regulations, the potential for point-of-care
processing, and ease of obtaining cells (in terms of time
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and resources). Allogeneic therapies have advantages over
autologous therapies in terms of patient throughput, prod-
uct consistency, quality control being applied to larger
lots, and treatment delays from processing failures [22].
Of the eight ATMPs licensed to date, five have been au-
tologous, two have been viral gene therapies (Glybera and
Imlygic) and one allogeneic (Zalmoxis).
The Cell and Gene Therapy Catapult is an organisation
dedicated to growing the UK cell and gene therapy industry
by bridging the gap between academic research and full
scale commercialisation. It promotes and develops the
existing early phase manufacturing network; the UK’s
small-scale academic facilities are a good source of mate-
rials for early-stage clinical trials although they are expected
to reach full capacity within a few years as the industry ma-
tures. With this in mind, the Catapults’ work will be aug-
mented by a £55 m large-scale manufacturing facility (due
to open in 2017) [23]. The centre aims to provide an infra-
structure to enable the manufacture of allogeneic or autolo-
gous cell therapies for later phase (II or III) clinical trials
and commercial scale-up. For developing businesses, this
will mean that finances need not be committed to a per-
manent commercial facility before it is known whether
products are going to be both clinically useful and econom-
ically viable. The vision is that successful products will
eventually be manufactured from purpose-built facilities
operated by successful firms. Input from organisations such
as the Cell and Gene Therapy Catapult could be crucial
since company size appears to be an independent predictor
of outcome of a marketing authorization application to the
EMA – the smaller the company, the more likely a negative
outcome. Direct interaction with regulators also appears to
be a key predictor of success [24].
Reimbursement by healthcare systems and evaluation of
cost-effectiveness
How should we value and price therapies which might
cure chronic or fatal diseases? How should we pay for
them? Claims of long-term benefits (perhaps even
cures), long-term safety issues due to persistence of
therapeutic cells, and significant up-front costs are issues
which raise particular challenges in the assessment of
the cost-effectiveness of regenerative medicines. Even
where there may be significant potential benefits over
current therapies, these may not be known with a high
level of certainty at the time of licensing [8, 9]. Further-
more, a key difference between regenerative medicines
and conventional medicines is the possibility that ther-
apies may change over time. For example, when the
ATMPs MACI and ChondroCelect (treatments for knee
cartilage defects) were assessed by NICE they were third
generation products. This may pose further uncertainty
problems since by the time long-term trial results be-
come available, the particular studied therapy may well
have been superseded by a (apparently superior) next-
generation treatment.
For EMA licensing purposes, a sponsor must demon-
strate a favourable benefit-risk balance. However, the
level of evidence required to achieve this can be less
than that needed to estimate the relative effectiveness
compared to current practice, or to quantify long-term
treatment benefits. Since this latter information is
essential for reliable assessment of cost-effectiveness, de-
velopers may find it is more difficult to demonstrate
cost-effectiveness for reimbursement than it is to dem-
onstrate efficacy for licensing. Schemes that allow devel-
opment of further evidence or entail a risk-sharing
component (between the payer and the manufacturer)
may therefore be required.
Managed entry agreements or performance-based risk
sharing agreements (PBRSAs) are an increasingly common
policy response for dealing with evidence base uncertainty.
PBRSAs involve the performance of treatments being
tracked in a defined patient population over a specified
time period, with the level or continuation of reimburse-
ment based on the health and economic outcomes
achieved. PBRSAs fall under a variety of names and cat-
egories such as outcomes-based schemes, risk-sharing
agreements, coverage with evidence development, access
with evidence development, conditional licensing and man-
aged entry schemes. Patient access schemes may also some-
times be linked to performance. There has always been
much uncertainty about the ultimate real-world clinical
and economic performance of new products; PBRSAs rep-
resent one mechanism for reducing this uncertainty [25].
Concern surrounding the potential high up-front costs
of regenerative medicines and their affordability to
healthcare systems means that alternative financing ap-
proaches may also have to be considered. These include
pay for performance, where the total price is more dir-
ectly related to therapy performance in clinical practice,
and amortisation, where payments are spread over the
expected duration of benefits [26]. The appropriateness
of employing different discount rates and/or different
rates over time is also an area requiring careful consider-
ation, particularly for potentially curative therapies.
Successful adoption of newly licensed ATMPs may
well depend on how they relate to existing clinical inter-
ventions. The manufacturer of ChrondroCelect – a li-
censed treatment for knee cartilage defects – recently
announced the initiation of the withdrawal of marketing
authorisation due to commercial reasons. The EMA’s
marketing authorisation for MACI (also a therapy for
knee cartilage defects) was suspended in September
2014 as an authorised manufacturing site no longer
existed (the developer closed the site). A key issue here
could be the availability of alternative, more cost-
effective treatments; indeed, established treatments such
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as microfracture surgery have long been available for
repairing knee cartilage defects. More recently, in
December 2016, the FDA gave marketing authorisation
to MACI in the USA, and Vericel will now try to build a
new market for it there. ATMPs are likely to be expen-
sive and these examples suggest that they may be most
likely to succeed commercially where there is an unmet
medical need.
Remaining hurdles and uncertainties
Despite reasons to be optimistic about the future of re-
generative medicine, further challenges abound. An im-
portant issue is that many therapies are currently used
without a licence from the EMA under “Hospital Ex-
emption” from the EC legislation (or via the “Specials”
scheme in the UK). Such treatments are prepared on a
non-routine basis according to specific quality standards
and are used for individual patients in a hospital under
the professional responsibility of a medical practitioner.
The problem is that hospital exemptions are regulated at
the national level, with different countries interpreting
the legislation in different ways; harmonisation and clar-
ity are needed in defining when treatments qualify.
There is concern about the risk that too broad a use of
hospital exemptions may deter the submission of mar-
keting authorisation applications to the EMA [27].
Careful consideration of longer-term adverse effect pro-
files is also important, as they may not be straightforward.
While many harms associated with pharmaceuticals may
improve following discontinuation, for regenerative medi-
cines, there is the possibility of prolonged harm, especially
where cells persist long-term. Developing effective methods
for inducing immune tolerance of allogeneic therapies also
remains a challenge. Patients receiving allogeneic cells may
need long-term immune suppression to avoid rejection.
More broadly, concerns have been raised that the evidence
for benefits to patients of adaptive pathway approaches is
lacking or contradictory [28]. There is also concern about
the follow-up evidence for some treatments granted condi-
tional approval by the EMA, with inconsistencies and de-
lays in the fulfilment of specific obligations [29, 30].
The optimum approach for manufacturing autologous
therapies is likely to be difficult to predict. Autologous
therapies can be manufactured centrally, although an ex-
ample of the type of difficulties encountered with some
centralised production models is provided by considering
Provenge (sipuleucel-T), a cell-based immunotherapy for
the treatment of prostate cancer. The process involved pa-
tient cells being cold-shipped to a manufacturing site,
where target immune cells were isolated and activated.
These were then cold-shipped back to the patient, re-
infused and the process repeated three times. The product
handling and manipulation was mostly manual, which led
to high product operating costs. Although efforts were
made to reduce costs by automating some process stages,
this example highlights the importance of considering
functionally closed and automated scale-out processes
early in clinical development [31]. In May 2015, the EU
marketing authorisation for Provenge was withdrawn at
the request of the manufacturer for commercial reasons.
An alternative approach to producing autologous therap-
ies centrally is scaling-out, rather than scaling-up (in a large
facility). Historical successful examples of the creative use
of existing multiple centres with technically-advanced facil-
ities include organ, bone-marrow and stem-cell transplants
[32]. However, achieving a high level of product quality
with decentralised models requires highly standardised, ro-
bust and transparent manufacturing processes and plat-
forms [33]. In-hospital micro-factories are also prominent,
particularly for autologous procedures that entail significant
surgery/patient contact; current examples include limbal
stem cell transplantation and the bioengineered trachea.
Nevertheless, whether multiple hospitals will be willing or
able to commit to good manufacturing practice under
licence is untested. The UK move towards ‘Cell and Gene
Therapy Treatment Centres’ as recommended by the
Advanced Therapies Manufacturing Taskforce (2016) [34]
poses new challenges for hospitals and the clinical science
system more generally in designing new treatment infra-
structures – with specific skills sets, logistical and equip-
ment demands, and regulatory oversight – for ATMPs.
Centralised production of autologous therapies may be seen
as more appropriate, as is currently happening with a
therapy (CTL019) being developed by Novartis; CTL019 is
one of a number of chimeric antigen receptor (CAR) T-cell
blood cancer therapies.
Providing a good illustration of many of the issues raised
in this article, CAR T-cell therapies are a regenerative
medicine to watch out for in the near future. They may
offer a potential cure for very ill patients with high unmet
medical needs – typically patients with refractory/relapsed
leukaemia – though they have potentially serious adverse
effects. In autologous CAR T-cell therapies a patient’s T-
cells are genetically modified, whereby the activated T-
cells can attack and destroy leukaemia B-cells. These ther-
apies have been under development for approximately
20 years, they are truly innovative and they have received
much press attention due to very encouraging early phase
trial results [8]; consequently, the use of a randomised
controlled design in further trials would not be ethical in
the patient populations being studied.
CAR T-cells are costly and complex to produce. For
Novartis’s CTL019 the initial work was carried out in an
academic setting with the treatments now being produced
in centralised large scale facilities in preparation for licens-
ing trials and marketing authorisation. Interestingly, in
terms of the viability and cost-effectiveness of manufac-
ture, CTL019 is being produced in the same facility as
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(the aforementioned) Provenge was. However, there
appear to be key differences between these therapies:
the benefits from CTL019 seem likely to be much
greater than those from Provenge and CTL019 is
frozen-shipped, so transportation and timing issues
should be minimised. Novartis bought the facility
from Dendreon, the biotech company that manufac-
tured Provenge.
The CAR T-cell example also highlights the import-
ance of adequately robust research both for marketing
authorisation and beyond. When to treat with CAR T-cells,
what pre-conditioning is needed, and how to manage tox-
icity due to cell persistence are just some of the issues
which will need resolving.
For future ATMPs, the importance and impact of the
many issues and possible solutions discussed here will
vary according to the specific therapy being developed.
An overview is presented in Fig. 1.
Conclusions
Despite the challenges involved in taking an ATMP from
laboratory to marketplace, the EMA’s approval of
Strimvelis and conditional approval of Holoclar provide
recent examples of successful collaboration between
publicly-funded researchers and the pharmaceutical
industry [35, 36]. Such collaborations could be the anti-
dote to the innovation crisis in the pharmaceutical in-
dustry, where much research is aimed at developing
safe-bet ‘me too’ drugs which offer little or no benefit
over treatments already available [37]. Collaboration
may allow closer attention to the patient pathway and
reduce time to market by ensuring more straightforward
adoption into clinical practice [38].
The more flexible regulatory landscape, more appro-
priate range of options for reimbursement and increas-
ing political interest and support structures do suggest a
brighter future for regenerative medicine – the licensing
Fig. 1 Overview of key stages and associated issues when bringing an advanced-therapy medicinal product to market in the EU
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of four ATMPs between 2015 and 2016 attest to this.
Nevertheless, only time will tell as to whether future
‘cure for blindness’ headlines reflect the probable, rather
than the possible.
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